5 FDA decisions to watch in the fourth quarter of 2026

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 01 Oct, 13:04 UTC

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.